Bliss GVS Pharma Limited (NSE:BLISSGVS, BSE:506197) today announced that its subsidiary Kremoint Pharma located at Ambernath in Maharashtra has cleared U.S. FDA inspection conducted on its facility during the period June 17th - 20th, 2019.
Commenting on the encouraging development, Mr. Gagan Harsh Sharma, VP-Strategy & Business Development, Bliss GVS Pharma Limited, said, "The successful audit outcome from U.S. FDA is a reflection of the steady progress that we are making into the mature pharma markets. This along with the completion of our OSD manufacturing unit located at Palghar shall further boost our growth into newer geographies."
Shares of BLISS GVS PHARMA LTD. was last trading in BSE at Rs.101.25 as compared to the previous close of Rs. 102.45. The total number of shares traded during the day was 231638 in over 2012 trades.
The stock hit an intraday high of Rs. 104.45 and intraday low of 98.9. The net turnover during the day was Rs. 23454314.